Cincor Pharma, Inc.(NASDAQ : CINC)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-3.01%||159.90||0.7%||$973.09m|
|MRK||Merck & Co., Inc.||-2.88%||77.68||0.7%||$846.95m|
|BMY||Bristol-Myers Squibb Co.||-2.58%||61.90||1.0%||$648.88m|
|LLY||Eli Lilly & Co.||-2.58%||236.79||1.1%||$603.24m|
|NVO||Novo Nordisk A/S||-1.38%||94.05||0.1%||$145.08m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||5.57%||116.21||0.0%||$77.84m|
|IMMX||Immix Biopharma, Inc.||-9.27%||4.09||0.0%||$64.49m|
CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism; as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Boston, MA.